Year: 2016
Type: review
Abstract: Except for management of Pseudomonas aeruginosa (PA) in cystic fibrosis, there are no approved inhaled antibiotic treatments for any other diseases or for infections from other pathogenic microorganisms such as tuberculosis, non-tuberculous mycobacteria, fungal infections or potential inhaled biowarfare agents including Francisella tularensis, Yersinia pestis and Coxiella burnetii (which cause pneumonic tularemia, plague and Q fever, respectively). Delivery of an antibiotic formulation via the inhalation route has the potential to provide high concentrations at the site of infection with reduced systemic exposure to limit side effects. A liposomal formulation may improve tolerability, increase compliance by reducing the dosing frequency, and enhance penetration of biofilms and treatment of intracellular infections. Two liposomal ciprofloxacin formulations (Lipoquin(®) and Pulmaquin(®)) that are in development by Aradigm Corporation are described here.
Source: Pharmaceutics
Authors: David Cipolla, Jim Blanchard, Igor Gonda
Institution: Aradigm (United States)
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Keywords: inhaled antibiotics, pulmonary infection, cystic fibrosis, Pseudomonas aeruginosa, biofilm penetration, intracellular infection, tuberculosis, nontuberculous mycobacteria, fungal lung infection, Francisella tularensis, Yersinia pestis, Coxiella burnetii, biological warfare agents, drug delivery
Open Access status: gold
Estimated APC paid: $3,499
OpenAlex ID: W2288730971
